The Pipeline

Home>News>The Pipeline

Importance of building Australia-China biotech collaborations

China is Australia’s greatest two-way trading partner in products and services, making up close to one-third of the nation’s international trade, as per the Australian Department of Foreign Affairs and Commerce. Resources and energy make up the largest share of Australia’s exports to China, with iron ore, natural gas and gold leading the way.

There are a number […]

2023-11-01T13:46:01+11:00November 1st, 2023|

Life Science Success podcast with Prof. Alan Trounson

Cartherics’ CEO, Prof. Alan Trounson, was recently a guest on Life Science Success podcast. Hosted by Dr Don Davies, this episode of the podcast discusses the future of cancer treatment and the importance of developing more precise and accessible treatment alternatives for patients with solid cancers.

Key discussion points from the podcast:

  • Alan Trounson has a […]
2023-10-20T09:42:22+11:00October 20th, 2023|

Cartherics appoints new Chief Scientific Officer

Melbourne, Australia, 17 October 2023 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has appointed Dr Walid Azar as Chief Scientific Officer (CSO), effective immediately. He holds extensive experience from a diverse scientific background encompassing both academic research and […]

2023-10-17T20:06:39+11:00October 17th, 2023|

Ovarian cancer is not ovarian cancer

Cartherics’ Dr Ian Nisbet (Chief Operating Officer) and Kathy Skoff (Clinical Trials Manager) recently attended an ovarian cancer symposium in Sydney, organised by Ovarian Cancer Australia and sponsored by AstraZeneca and GSK.  It was an excellent event, with an exceptional panel of speakers who provided overviews of the different types of ovarian cancer along with […]

2023-10-03T12:56:36+11:00October 3rd, 2023|

Combining new and existing immunity: a 3D approach to killing cancer

by Richard Boyd and Aleta Pupovac

A question which has long baffled scientists, frustrated clinicians and devastated patients is why does the immune system so effectively defend against infections but so poorly deal with cancer? What lessons can be learnt?

Thanks to a molecular biology-led revolution in immunotherapy, we are now beginning to strategically apply the immune […]

2023-09-25T08:03:23+10:00September 25th, 2023|

Bio Connections Australia 2023 promotes science commercialisation

Commercialising science and technology is key to the continued growth of Australia’s vibrant life sciences industry. Translating research into real-world results has important implications for consumers and businesses alike.

Bio Connections Australia 2023 was held today at Crown Promenade Melbourne with an important focus on translation, drug development and expediting Australia’s science into commercialisation.

The forum […]

2023-07-31T16:08:33+10:00July 31st, 2023|

Australia – China Science and Innovation Forum fosters collaboration and commercialisation

The 2023 Australia-China Science and Innovation Forum focused on leading-edge Australian and Chinese biomedical research collaborations and commercialisation. The forum was held at Monash University’s Suzhou campus in China last week and was also available for online attendance.

The forum’s program was designed to promote connections and enhance collaborations between the Australian and Chinese research and […]

2023-06-28T11:13:35+10:00June 28th, 2023|

Global IP takes centre stage at the 21st Advanced Summit on Life Sciences Patents

Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in New York City. The summit provided the opportunity to engage in face-to-face discussions with leading stakeholders on the best practices to enhance global protections for patent portfolios. Now more than ever in these increasingly […]

2023-05-30T15:08:10+10:00May 30th, 2023|

Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China

Melbourne, Australia, 28 April 2023 –  Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]

2023-04-28T13:00:59+10:00April 28th, 2023|

Cartherics proudly supports the White Shirt Campaign

Cartherics is hosting a White Shirt Day lunch on 8th May to help raise funds and awareness for ovarian cancer. The White Shirt Campaign officially launches on April 11th and culminates on White Shirt Day (8 May) – World Ovarian Cancer Day.

The campaign is a 15-year partnership between the Ovarian Cancer Research Foundation (OCRF) […]

2023-05-24T13:40:22+10:00April 11th, 2023|
Go to Top